Utah Medical Products Inc
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -2.3% | -3.3% | +21.1% | +7.6% | +10.0% | +1.8% | +3.5% | +7.1% | +9.4% | -9.5% | +0.0% | |
| – | +10.8% | +6.1% | +41.1% | +23.8% | -9.9% | +13.4% | +17.5% | +22.9% | +18.2% | -9.4% | +1.5% | |
| – | +20.7% | +13.0% | +51.3% | +28.2% | -16.3% | +20.6% | +18.2% | +23.1% | +23.7% | -10.7% | +3.4% | |
| – | +20.7% | +13.0% | +51.6% | +27.9% | -16.3% | +20.6% | +18.2% | +23.1% | +23.7% | -10.7% | +3.4% | |
| – | +17.6% | -29.6% | +12.8% | +9.2% | +19.9% | -13.5% | +25.0% | +7.9% | -38.8% | +20.8% | -14.0% | |
| – | -13.9% | +8.2% | +15.5% | +3.2% | +27.7% | -10.0% | +6.0% | +33.6% | +8.7% | -8.0% | -10.0% | |
| – | -10.5% | +35.2% | +16.6% | -10.9% | +3.6% | +5.6% | -2.9% | -7.0% | – | – | – | |
| – | -2.8% | -8.4% | +4.5% | -2.8% | +1.9% | +1.5% | -0.5% | -5.3% | +2.5% | -0.8% | +3.5% | |
| – | -13.6% | -24.6% | -2.3% | -17.0% | +104.1% | -20.6% | -26.0% | -41.6% | -52.3% | -42.1% | -70.7% | |
| – | -42.3% | -23.0% | +99.2% | -26.3% | -19.3% | +2.6% | -4.8% | +13.2% | -25.7% | -28.5% | -35.9% | |
| – | -54.7% | -25.7% | +74.7% | -0.4% | -34.4% | +9.9% | -1.2% | +59.1% | -21.0% | -20.2% | -30.8% | |
| – | – | – | – | – | – | +7.9% | +26.8% | +3.8% | -13.0% | +19.1% | – | |
| – | -30.1% | +39.6% | +3.1% | +4.4% | +12.6% | -28.2% | -3.4% | +60.1% | -36.9% | -29.4% | +67.8% | |
| – | -100.0% | – | – | – | – | – | – | – | – | – | – | |
| – | +7.9% | -0.6% | +12.8% | +13.9% | +13.6% | +1.7% | +4.2% | +6.6% | +12.3% | -8.5% | +1.6% | |
| – | +12.3% | +11.3% | +5.6% | +16.9% | +10.7% | +0.1% | +3.9% | +9.3% | +9.8% | -6.5% | -0.5% | |
| – | -0.1% | -0.1% | -0.8% | +0.3% | -0.2% | -1.8% | -0.3% | -0.5% | -0.2% | -3.7% | -7.5% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.